FindTrial
Sign In

A new drug for hair loss- Tofacitinib

EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH ALOPECIA AREATA INVOLVING MORE THAN 50% OF SCALP SURFACE AREA: A DOUBLE BLIND RANDOMIZED CONTROLLED TRIAL.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/09/045386
Enrollment
38
Registered
2022-09-09
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L639- Alopecia areata, unspecified

Interventions

Intervention1: Tofacitinib: Janus Kinase - 1/3 inhibitor, 5mg BD given for 16 weeks Control Intervention1: Betamethasone pulse: Systemic steroid-5mg twice weekly for 16 weeks

Sponsors

Department of Dermatology venereology and leprosy Burdwan medical college and hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Alopecia areata involving more than 50% of scalp surface area. Age- 15-60 years

Exclusion criteria

Exclusion criteria: Immunosupressed patients like HIV,TB, Hepatitis Patients on chemotherapy. Pregnancy and lactation Patients with psoriasis or seborrhoeic dermatitis. Patients treated with any topical or systemic therapy within 3 month of 1st visit

Design outcomes

Primary

MeasureTime frame
Primary- to compare the response of treatment in 2 group alloted. secondary- to evaluate safety of drugTimepoint: Treatment to be given for 16 weeks and follow up 12 weeks—

Secondary

MeasureTime frame
Comparing maintenance of response post treatment along with assessment of side effectsTimepoint: After every month during treatment and follow up period—

Countries

India

Contacts

Public ContactDR KAUSHIK SHOME

BURDWAN MEDICAL COLLEGE

roy2014anupam@gmail.com9609652919

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026